MEK2 knockdown increases sensitivity to chemotherapy. Western blot for MEK2 in the control NT cell line and in the shRNA-expressing Reh (A, top) and RS4;11 cell lines (B, top). NT and MEK2-targeting shRNA Reh (A) and RS4;11 cells (B) were treated with increasing concentrations of prednisolone (middle) or doxorubicin (bottom) for 24 hours. Cell viability was measured by CellTiter-Glo assay. *P ≤ .05. Cell viability assays for MEK4 and MEK2 were performed in the same experiment and compared to the same control NT. The bars for the control NT are the same in this figure as shown in Figure 2. We have separated the graphs for simplicity.